Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis

Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and hemodynamic and metabolic responses to 6 months treatment with atrasentan, the selective endothelin-A receptor antagonist. Seventy-two patients with multiple cardiovascular...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hypertension (Dallas, Tex. 1979) Tex. 1979), 2008-09, Vol.52 (3), p.522-528
Hauptverfasser:	Raichlin, Eugenia, Prasad, Abhiram, Mathew, Verghese, Kent, Bailey, Holmes, Jr, David R, Pumper, Geralyn M, Nelson, Rebecca E, Lerman, Lilach O, Lerman, Amir
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antihypertensive Agents - administration & dosage Antihypertensive Agents - adverse effects Blood Glucose - metabolism Blood Pressure - drug effects Coronary Artery Disease - drug therapy Coronary Artery Disease - epidemiology Edema - drug therapy Edema - epidemiology Endothelin A Receptor Antagonists Endothelin-1 - metabolism Female Follow-Up Studies Humans Hypertension - drug therapy Hypertension - epidemiology Kidney - physiology Lipid Metabolism - drug effects Male Metabolic Syndrome - drug therapy Metabolic Syndrome - epidemiology Middle Aged Pyrrolidines - administration & dosage Pyrrolidines - adverse effects Receptor, Endothelin A - metabolism Risk Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and hemodynamic and metabolic responses to 6 months treatment with atrasentan, the selective endothelin-A receptor antagonist. Seventy-two patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary angiogram were randomly assigned in a double-blind manner to atrasentan or placebo. Mean aortic blood pressure decreased from 92+/-10 to 80+/-10 mm Hg (P
ISSN:	0194-911X 1524-4563
DOI:	10.1161/HYPERTENSIONAHA.108.113068